Citations

Clear

3138 citation(s) found for "Smith, AM".

Soluble mesothelin neutralizes mesothelin antibody-based therapies.
Ayers-Ringler, Jennifer , Dizona, Paul, Kim, Yohan, Orme, Jacob J. , Moscow, Jeffrey A. , Moscow, Jeffrey A , Smith, Katherine E. , Lucien, Fabrice , Winters, Jeffrey L. , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 2565-2565

10.1200/jco.2024.42.16_suppl.2565 Get It

2565 Background: Mesothelin (MSLN) is overexpressed in mesothelioma and other solid tumors making it the focus of multiple targeted therapies, including antibody drug conjugates (ADCs), T cell receptor (TCR) fusion constructs, and chimeric antigen receptor T-cell (CAR-T) products. However, the clinical efficacy of these treatments remains limited. We hypothesize that soluble MSLN (sMSLN) in the plasma binds to MSLN-targeted therapies before reaching the tumor. Our study aimed to evaluate the effects of sMSLN on a MSLN-targeting antibody, anetumab, and explore methods to reduce sMSLN. Methods: Exploratory analysis in NCT03126630: sMSLN testing was performed on blood samples from participants enrolled in NCT03126630 at the Molecular Targets Core Lab, National Cancer Institute. The median was used to categorize high and low levels of sMSLN. Survival was estimated with the Kaplan-Meier method and compared between groups with the log rank test. Anetumab immunoprecipitation: Anetumab was covalently coupled to Dynabeads at 5 µg per mg of beads to immunoprecipitate MSLN from two plasma samples. Assays were performed in duplicate. Therapeutics plasma exchange (TPE):Whole blood samples were collected before and after one plasma volume of TPE with albumin as the replacement fluid in patients undergoing routine TPE for various medical conditions, such as autoimmune diseases and hyperviscosity syndromes. Plasma levels of sMSLN were measured with an ELISA assay in matched pre- and post-TPE plasma samples. Results: We obtained sMSLN levels from 40 patients enrolled in NCT03126630. For patients treated with both anetumab ravtansine and pembrolizumab, median progression free survival (PFS) was shorter in the high sMSLN group (5 months) vs the low sMSLN group (12 months). For patients treated with pembrolizumab alone, PFS was similar for patients with high and low sMSLN (4 vs 3.4 months). Anetumab significantly reduced the concentration of sMSLN in plasma samples as detected by MSLN ELISA (p<0.05), demonstrating that sMSLN can bind to and sequester anetumab. Next, we evaluated TPE as a mechanism to reduce sMSLN. We obtained pre- and post-TPE plasma samples from 15 patients undergoing routine TPE for various medical conditions. TPE consistently reduced sMSLN (p<0.05) with an average decrease of 43.6% or 15.4 ng/mL. Conclusions: We found that high sMSLN levels are associated with shorter PFS for anetumab ravtansine, but not pembrolizumab. Additionally, anetumab binds to sMSLN in the plasma, which suggests that sMSLN can sequester anti-MSLN antibodies and may limit the efficacy of MSLN-targeted therapies. High levels of sMSLN could potentially be used as a biomarker to select which patients should not receive MSLN-targeting therapies. Furthermore, our results indicate that sMSLN reduction is feasible with TPE. Decreasing sMSLN could restore the activity of MSLN-targeted therapies.
Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience.
Hoppenworth, Jenna, Premji, Sarah , Smith, Deanne, Taraba, Jodi L. , Hobday, Timothy J. , Peethambaram, Prema P. , Carroll, Jamie M. , Ruddy, Kathryn J. , O’Sullivan, Ciara C. , Choong, Grace M. , Ellsworth, L., Rao, Rohit , Egan, Ashley, Haddad, Tufia C. , Leon‐Ferre, Roberto A. , Taraba, Jodi L , Tevaarwerk, Amyé , Cathcart-Rake, Elizabeth , Yadav, Siddhartha , Rao, Rohit, Goetz, Matthew P. , Giridhar, Karthik V.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11145-11145

10.1200/jco.2024.42.16_suppl.11145 Get It

11145 Background: T-DXd is increasingly used in mBC. A T-DXd toxicity of special interest is interstitial lung disease/pneumonitis (ILD), occurring in 10-15% of pts in the DESTINY-Breast trials, and with potential lower incidence/severity in earlier line settings [Krop et al, ASCO 2023]. However, in routine practice, T-DXd may be used in pts with more heavily pre-treated mBC and previously exposed to other antibody-drug conjugates (ADC) [Premji et al SABCS 2023]. We evaluated the incidence/severity of T-DXd related ILD in mBC at Mayo Clinic. Methods: We retrospectively identified pts with mBC who received ≥1 dose of T-DXd at Mayo Clinic, Rochester, MN, between July 2022-December 2023. Demographic, mBC, and pulmonary clinical variables were abstracted from the clinical records. Data was summarized using descriptive statistics. Diagnosis of ILD was determined by treating clinicians, and severity to CTCAE V5 based on clinical documentation. Results: 77 pts with mBC received T-DXd during the study period. All were female, the majority (70, 91%) were Caucasian, and median age was 58. 53 (69%) had HER2-low mBC (37 HR+, 16 HR-) and 24 (31%) had HER2+ mBC (17 HR+, 7 HR-). 31 (40%) were active or former smokers. 11 (14%) had pulmonary comorbidities, including 6 (7.8%) with asthma, 2 (2.6%) with prior pneumonitis, and 3 (3.9%) with other pulmonary comorbidities. They had previously received a median of 1 line of endocrine therapy, and 4 lines of chemotherapy, with 20 (26%) having received another ADC. 17 (22%) developed any grade ILD [G1: 3 (4%), G2: 7 (9%), G3: 2 (3%), G4: 1 (1%), G5: 4 (5%)]. Among pts with ILD of any grade, 13 (76.5%) presented with at least 1 symptom (cough/SOB). The median number of T-DXd cycles prior to onset of any grade ILD was 6 (range 2-13), or 18 (range 6-39) weeks. 5 (29%) pts with any grade ILD received a prior ADC. Of pts with ≥G3 ILD (n=7), all were Caucasian, 2 (30%) were prior smokers, none had prior lung disease, and had received a median of 5 prior lines of chemo, with 4 (57%) having received a prior ADC. All grade ≥2 ILDs were treated with systemic steroids, and 1 also received IVIG. CT chest was used for diagnosis of all ILD. 7 pts (41%) required hospitalization, all of whom had bronchoscopy, with 5 (29%) requiring intubation. All pts with G1 ILD (3, 18%) restarted T-DXd without ILD recurrence. Conclusions: In this case series,22% of ps treated with T-DXd experienced ILD (5% G5), higher than the rate observed in the pivotal DESTINY-Breast trials, possibly due to real-world use of T-DXd in more heavily pre-treated pts and in pts with pulmonary comorbidities.
SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Pachman, Deirdre R. , Ruddy, Kathryn J. , Grzegorczyk, Veronica , Chlan, Linda L., Leventakos, Konstantinos , Strand, Jacob J. , Kroenke, Kurt , Griffin, Joan M. , Ridgeway, Jennifer L. , Tofthagen, Cindy , Austin, Jessica D. , Smith, Ashley Wilder , Mitchell, Sandra A , Herrin, Jeph , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11108-11108

10.1200/jco.2024.42.16_suppl.11108 Get It

11108 Background: Advances in cancer treatment have led to a growing population of patients living with metastatic cancer. Symptom burden for these patients is understudied. Our objective is to report the prevalence and severity of SPPADE symptoms (sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy /fatigue) in a large cohort of patients with metastatic cancer. Methods: These data are drawn from the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) stepped wedge pragmatic trial evaluating a symptom management intervention for cancer patients (NCT03892967). This analysis was limited to those identified with metastatic disease using ICD- codes and a natural language processing algorithm prior to or within 30 days of their baseline symptom survey. Symptom severity was measured on a 0-10 scale with scores of 1-3 categorized as “mild”, 4-6 as “moderate”, and ≥7 as “severe.” A SPPADE composite score was calculated by summing six individual symptom scores and is an indicator of total symptom burden. We report descriptive statistics for each symptom by severity category. We also test for differences in SPPADE composite score by race, disability status, employment status, education and cancer type using Kruskal-Wallis tests. Results: 12,824 patients with metastatic disease completed a survey between March 2019 and January 2023. Discretized score distributions for the SPPADE symptoms are reported in the Table. The SPPADE composite mean score for the cohort was 17.6 (SD +/- 12.0). Significant differences were found in total symptom burden by sociodemographic and clinical characteristics ( p<0.01): Higher total symptom burden (Mean [SD])was experienced by individuals who were American Indian/Alaska Native (AI/AN) (23.8[13.5]) or African American (AA) (20.5[14.7]), disabled (24.0[12.8]) or unemployed (21.1[13.0]), and had a high school education (20.0[13.3]) or less than high school education (18.5[12.4]). There were also statistically significant differences ( p<0.01) in symptom burden across cancer types, with patients with metastatic lung cancer reporting the highest symptom burden (20.0[12.2]) and those with metastatic melanoma reporting the lowest (14.7[11.4]). Conclusions: SPPADE symptoms are common in patients with metastatic cancer, especially fatigue, sleep disturbance, and physical function impairment. Symptom burden is especially high in AI/AN, AA, disabled/unemployed, and less educated patients. Further research is needed to tailor symptom interventions among those living with metastatic disease. [Table: see text]
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Smith, Mitchell R. , Jegede, Opeyemi A. , Parekh, Samir , Yang, David T. , Hsi, Eric D. , Witzig, Thomas E. , Davé, Sandeep S. , Scott, David W. , Hanson, Curtis A. , Shields, Lale Kostakoglu, Abdel‐Samad, Nizar, Baghdadi, Tareq Al, Blum, Kristie A. , Romer, Mark D., Inwards, David J. , Lerner, Rachel E. , Little, Richard F. , Friedberg, Jonathan W. , Leonard, John P. , Witzig, T.E. , Yang, David , Hsi, Eric D , Scott, David W , Hanson, Curtis, Casulo, Carla , Wagner, Lynne , Little, Richard F , Kahl, Brad S , Jagede, Opeyemi A. , Parekh, Samir , Baghdadi, Tareq Al , Martin, Peter, Till, Brian G. , Casulo, Carla , Bartlett, Nancy L. , Caimi, Paolo F. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Blood | May 31, 2024 | Volume: 144 | Issue: 10 | Pages: 1083-1092

10.1182/blood.2024023962 | PMID 38820500 Get It

Abstract Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? From 2012 to 2016, 373 previously untreated patients, 87% aged ≥60 years, were enrolled in this trial. At a median follow-up of 7.5 years, there is no difference in the median PFS of BR compared with BVR (5.5 vs 6.4 years; hazard ratio [HR], 0.90; 90% confidence interval [CI], 0.70-1.16). There were no unexpected additional toxicities with BVR treatment compared with BR, with no impact on total dose/duration of treatment received. Independent of the induction treatment, addition of lenalidomide did not significantly improve PFS, with median PFS in R vs LR (5.9 vs 7.2 years; HR, 0.84; 90% CI, 0.62-1.15). Most patients completed the planned 24 cycles of LR at the scheduled dose. In summary, adding bortezomib to BR induction does not prolong PFS in treatment-naïve MCL, and LR maintenance was not associated with longer PFS compared with R alone after BR. Nonetheless, the &gt;5-year median PFS outcomes in this prospective cooperative group trial indicate the efficacy of BR followed by R maintenance as highly effective initial therapy for older patients with MCL. This trial was registered at www.clinicaltrials.gov as #NCT01415752.
Autoimmune‐associated seizure disorders
Smith, Kelsey M. , Budhram, Adrian , McKeon, Andrew, Stredny, Coral M. , Titulaer, Maarten J. , Budhram, Adrian , Smith, Kelsey M , Titulaer, Maarten J , Geis, Christian , McKeon, Andrew , Steriade, Claude , Britton, Jeffrey W.

Mayo Clinic

Epileptic Disorders | May 31, 2024 | Volume: 26 | Issue: 4 | Pages: 415-434

10.1002/epd2.20231 | PMID 38818801 Get It

AbstractWith the discovery of an expanding number of neural autoantibodies, autoimmune etiologies of seizures have been increasingly recognized. Clinical phenotypes have been identified in association with specific underlying antibodies, allowing an earlier diagnosis. These phenotypes include faciobrachial dystonic seizures with LGI1 encephalitis, neuropsychiatric presentations associated with movement disorders and seizures in NMDA‐receptor encephalitis, and chronic temporal lobe epilepsy in GAD65 neurologic autoimmunity. Prompt recognition of these disorders is important, as some of them are highly responsive to immunotherapy. The response to immunotherapy is highest in patients with encephalitis secondary to antibodies targeting cell surface synaptic antigens. However, the response is less effective in conditions involving antibodies binding intracellular antigens or in Rasmussen syndrome, which are predominantly mediated by cytotoxic T‐cell processes that are associated with irreversible cellular destruction. Autoimmune encephalitides also may have a paraneoplastic etiology, further emphasizing the importance of recognizing these disorders. Finally, autoimmune processes and responses to novel immunotherapies have been reported in new‐onset refractory status epilepticus (NORSE) and febrile infection‐related epilepsy syndrome (FIRES), warranting their inclusion in any current review of autoimmune‐associated seizure disorders.
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
Smith, Caleb J. , Grierson, Patrick , Morelli, Maria Pia , Patel, Sandip Pravin , Ulrickson, Matthew L. , Dahiya, Saurabh , Liechty, Kirstin B., Tebbets, Jessica , Welch, John S. , Go, William Y., Maloney, David G. , Ng, Eric Wai-Choi , Hecht, J. Randolph, Simeone, Diane M. , Kirtane, Kedar , Park, Jong Chul , Specht, Jennifer M. , Fakih, Marwan , Maus, Marcela V

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1604-1604

10.1200/jco.2024.42.16_suppl.1604 Get It

1604 Background: Diversity in clinical studies is essential to address health disparities, but racial and ethnic minorities are often underrepresented in clinical studies, especially in precision medicine studies using genetic data (1). BASECAMP-1 (NCT04981119) is an ongoing prescreening study to identify patients with unresectable advanced or metastatic solid tumors and tumor-associated HLA-A*02 LOH for the EVEREST-1 and -2 Tmod chimeric antigen receptor T-cell therapy trials. When enrollment began in 2021, eligibility for Part 1 was restricted to patients with germline HLA-A*02:01 based on preclinical data. Additional analysis revealed the blocker in the Tmod construct had activity across HLA-A*02 subtypes (Mock, et al. Mol Ther Oncolytics.2022). Eligibility for Part 1 was then expanded to all HLA-A*02 subtypes, allowing enrollment of more diverse patient populations. HLA-A*02 allele subtypes vary by ethnicity and race; the frequency of HLA-A*02:01 is 96% in non-Hispanic Whites, but ranges from 53% to 73% in other ethnicities and races. The frequency of all other HLA-A*02 allele subtypes (HLA-A*02:XX) is <5% in non-Hispanic Whites but up to 66% in other ethnicities and races (2,3). Methods: Patients eligible for BASECAMP-1 were identified at United States study sites. All patients screened before January 16, 2024, for Part 1 were included for demographic and central lab HLA-A typing. The % increase in eligibility and % of heterozygous HLA-A*02 patients with HLA-A*02:XX were calculated by ethnicity and race. Results: A total of 1124 patients were screened for germline HLA-A*02 typing; 431 patients were HLA-A*02:01 heterozygous, of whom 37 (9%) were Hispanic, 14 (3%) African American (AA), 2 (<1%) American Indian or Alaska Native, 17 (4%) Asian or Pacific Islander (API), and 324 (75%) non-Hispanic White (Table). The eligibility expansion identified 62 patients with HLA-A*02:XX heterozygosity, of whom 6 (10%) were Hispanic, 6 (10%) AA, 19 (31%) API, and 25 (40%) non-Hispanic White. Conclusions: By expanding enrollment to include HLA-A*02:XX, 16% more Hispanic, 43% more AA, and 112% more API patients were identified, improving the diversity in this trial compared with that of initial enrollment. 1. Aldrighetti, et al. JAMA Netw Open 2021. 2. Ellis, et al. Human Immunol. 2000. 3. Gragert, et al. Human Immunol.2013. Clinical trial information: NCT04981119 . [Table: see text]
Anaplastic sarcoma of the kidney ( DICER1 ‐sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/ DICER1 Registry
Schoettler, Peter , Smith, Caroline , Nishitani, Miki , Harris, Anne K. , Nelson, Alexander T. , Watson, Dave A., Kamihara, Junne , Mullen, Elizabeth A. , Messinger, Yoav H. , Fair, Douglas , Dehner, Louis P. , Ash, Shifra , Schultz, Kris Ann P. , Messinger, Yoav H , Fair, Douglas B , Ash, Shifra , Chen, Kenneth S , Schultz, Kris Ann P , Watson, Dave , Hill, Dana Ashley , Kumar, Kiran Achut , Chen, Kenneth

Mayo Clinic

Pediatric Blood & Cancer | May 28, 2024 | Volume: 71 | Issue: 8 | Pages: No page available

10.1002/pbc.31090 | PMID 38807260 Get It

Abstract Background Anaplastic sarcoma of the kidney (ASK) is a DICER1 ‐related neoplasm first identified as a distinctive tumor type through the evaluation of unusual cases of putative anaplastic Wilms tumors. Subsequent case reports identified the presence of biallelic DICER1 variants as well as progression from cystic nephroma, a benign DICER1 ‐related neoplasm. Despite increasing recognition of ASK as a distinct entity, the optimal treatment remains unclear. Methods Individuals with known or suspected DICER1 ‐related tumors including ASK were enrolled in the International Pleuropulmonary Blastoma/ DICER1 Registry. Additionally, a comprehensive review of reported cases of ASK was undertaken, and data were aggregated for analysis with the aim to identify prognostic factors and clinical characteristics to guide decisions regarding genetic testing, treatment, and surveillance. Results Ten cases of ASK were identified in the Registry along with 37 previously published cases. Staging data, per Children's Oncology Group guidelines, was available for 40 patients: 13 were stage I, 12 were stage II, 10 were stage III, and five were stage IV. Outcome data were available for 37 patients. Most (38 of 46) patients received upfront chemotherapy and 14 patients received upfront radiation. Two‐year event‐free survival (EFS) for stage I–II ASK was 81.8% (95% confidence interval [CI]: 67.2%–99.6%), compared with 46.6% EFS (95% CI: 24.7%–87.8%) for stage III–IV ( p = .07). Two‐year overall survival (OS) for stage I–II ASK was 88.9% (95% CI: 75.5%–100.0%), compared with 70.0% (95% CI: 46.7%–100.0%) for stage III–IV ( p = .20). Chemotherapy was associated with improved EFS and OS with hazard ratios of 0.09 (95% CI: 0.02–0.31) and 0.08 (95% CI: 0.02–0.42), respectively. Conclusion ASK is a rare DICER1 ‐related renal neoplasm. In the current report, we identify clinical and treatment‐related factors associated with outcome including the importance of chemotherapy in treating ASK. Ongoing data collection and genomic analysis are indicated to optimize outcomes for children and adults with these rare tumors.
Exaggerated Inspiratory Muscle Metaboreflex in Arterial Hypertension
Cifci, Gizem , Bruhn, Eric J., Bissen, Thomas G. , Olson, Thomas P. , Smith, Joshua R. , Smith, Joshua R

Mayo Clinic

Journal of the American Heart Association | May 28, 2024 | Volume: 13 | Issue: 11 | Pages: No page available

10.1161/jaha.123.033511 | PMID 38804227 Get It

ICSNT Primer for the Skull Base Community: Navigating the Landscape of Sinonasal Tumors with Synthesized Literature Guidance
Adappa, Nithin D. , London, Nyall R. , Smith, Timothy L. , Su, Shirley Y. , Wang, Marilene B. , Adappa, Nithin D. , Kuan, Edward C , Holtzman, Adam L. , Wang, Marilene B , Su, Shirley Y , Wang, Eric W , Adappa, Nithin D. , Beswick, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 23, 2024 | Volume: 86 | Issue: 03 | Pages: 373-376

10.1055/s-0044-1787155 | PMID 40351885 Get It

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer
Chen, Anran , Kim, Beom-Jun , Mitra, Aparna , Vollert, Craig T. , Fandino, Diana , Anurag, Meenakshi , Holt, Matthew V. , Gou, Xuxu , Pilcher, Jacob B. , Northfelt, Donald W. , Marshall, C. Gary , Hyer, Marc L. , Papp, Robert , Yin, Shou-Yun , Angelis, Carmine De , Cynthia, X. , Lei, Jonathan T , Fandino, Diana , Anurag, Meenakshi , Holt, Matthew V , Gou, Xuxu , Pilcher, Jacob B , Goetz, Matthew P , Northfelt, Donald , Hilsenbeck, Susan Galloway , Marshall, C Gary , Hyer, Marc L , Papp, Robert , Yin, Shou-Yun , De Angelis, Carmine , Schiff, Rachel , Fuqua, Suzanne A W , Ma, Cynthia , Foulds, Charles E , Ellis, Matthew J , Lei, Jonathan T. , Goetz, Matthew P. , Schiff, Rachel , Ellis, Matthew J.

Mayo Clinic

Molecular Cancer Therapeutics | May 23, 2024 | Volume: 23 | Issue: 10 | Pages: 1494-1510

10.1158/1535-7163.mct-23-0564 | PMID 38781103 Get It

Abstract Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-α-positive (ER+) breast cancer, however drug resistance is common. In this study, proteogenomic analyses of patient-derived xenografts (PDXs) from patients with 22 ER+ breast cancer demonstrated that protein kinase, membrane-associated tyrosine/threonine one (PKMYT1), a WEE1 homolog, is estradiol (E2) regulated in E2-dependent PDXs and constitutively expressed when growth is E2-independent. In clinical samples, high PKMYT1 mRNA levels associated with resistance to both ET and CDK4/6 inhibition. The PKMYT1 inhibitor lunresertib (RP-6306) with gemcitabine selectively and synergistically reduced the viability of ET and palbociclib-resistant ER+ breast cancer cells without functional p53. In vitro the combination increased DNA damage and apoptosis. In palbociclib-resistant, TP53 mutant PDX-derived organoids and PDXs, RP-6306 with low-dose gemcitabine induced greater tumor volume reduction compared to treatment with either single agent. Our study demonstrates the clinical potential of RP-6306 in combination with gemcitabine for ET and CDK4/6 inhibitor resistant TP53 mutant ER+ breast cancer.